Lu Haijia, Wang Huahao, Zhao Hongyi, Zhang Dongfeng
Beijing Key Laboratory of Active Substance Discovery & Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, China.
Future Med Chem. 2022 Aug;14(15):1149-1165. doi: 10.4155/fmc-2022-0079. Epub 2022 Jul 22.
Tuberculosis (TB) is an infectious and fatal disease caused by () and remains a serious public health threat; therefore, the development of new antitubercular agents is a priority for the World Health Organization's End TB strategy and the United Nations' Sustainable Development Goals to eradicate TB. Oxazolidinones are a class of synthetic antibacterial agents with a distinct mode of action developed for the treatment of Gram-positive bacterial infections. Many oxazolidinones exhibit good activity against , and some are currently in clinical trials for multidrug-resistant TB and extensively drug-resistant TB therapy. In this review, the mechanism of action, activity and toxicity of oxazolidinones and recent progress in the research and development of oxazolidinones as anti-TB agents are summarized.
结核病(TB)是由()引起的一种传染性致命疾病,仍然是严重的公共卫生威胁;因此,开发新型抗结核药物是世界卫生组织终结结核病战略和联合国消除结核病可持续发展目标的优先事项。恶唑烷酮类是一类具有独特作用方式的合成抗菌剂,用于治疗革兰氏阳性菌感染。许多恶唑烷酮类对()表现出良好活性,一些目前正处于耐多药结核病和广泛耐药结核病治疗的临床试验中。在本综述中,总结了恶唑烷酮类的作用机制、活性和毒性以及作为抗结核药物的研发最新进展。